Galcanezumab reduces trigeminal nociception and is effective in preclinical models of migraine and trigeminal autonomic cephalalgias.
Saved in:
| Title: | Galcanezumab reduces trigeminal nociception and is effective in preclinical models of migraine and trigeminal autonomic cephalalgias. |
|---|---|
| Authors: | Vila-Pueyo M; Headache Group, Wolfson Sensory Pain and Regeneration Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK., Goadsby PJ; Headache Group, Wolfson Sensory Pain and Regeneration Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK., Johnson KW; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Holland PR; Headache Group, Wolfson Sensory Pain and Regeneration Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK. |
| Source: | Headache [Headache] 2025 Nov-Dec; Vol. 65 (10), pp. 1693-1703. Date of Electronic Publication: 2025 Jul 21. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 2985091R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-4610 (Electronic) Linking ISSN: 00178748 NLM ISO Abbreviation: Headache Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1526-4610 |
|---|---|
| DOI: | 10.1111/head.15006 |
